Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wells Fargo analyst Yanan Zhu maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $400 to $435.
Wells Fargo analyst Yanan Zhu maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $400 to $435.
